中轴型脊柱关节炎预后分层框架最终验证:健康相关生活质量的纵向决定因素
基于Devenir des Spondylarthropathies Indifférenciées Récentes队列663例症状<3年的axSpA患者随访10年,采用广义估计方程模型分析ASDAS和BASFI与HRQoL(PCS、MCS、ASQoL)的纵向关联。自回归模型中ASDAS和BASFI均与HRQoL显著相关,BASFI对HRQoL的影响大于ASDAS,ASDAS对HRQoL的作用约75%由BASFI介导,约25%为直接效应。
要点
- 自回归模型中ASDAS与PCS的β为-2.93,BASFI与PCS的β为-2.13。
- BASFI对HRQoL的影响大于ASDAS。
- ASDAS对HRQoL的作用约75%由BASFI介导,约25%为直接效应。
核心结论
- 建立了经过验证的纵向框架用于解读HRQoL:即使校正背景因素,疾病活动度仍持续影响HRQoL,主要经功能损害介导,也存在直接效应。
- HRQoL是axSpA的总体结局,但达标治疗低疾病活动度对优化HRQoL至关重要。
研究设计与样本
- 来自Devenir des Spondylarthropathies Indifférenciées Récentes队列的症状<3年axSpA患者,随访10年。
- 共纳入663例患者(46%男性,平均年龄33.5[8.6]岁)。
- 采用多变量广义估计方程模型,以PCS、MCS或ASQoL为结局,ASDAS和BASFI为主要预测因子,使用标准模型和自回归模型(校正既往HRQoL),通过标准化系数比较ASDAS与BASFI对HRQoL的影响,并进行中介分析。
主要发现
- 自回归多变量模型中,ASDAS与PCS的β系数为-2.93(95%CI -3.28至-2.58),BASFI与PCS的β系数为-2.13(95%CI -2.31至-1.96)。
- 自回归多变量模型中,ASDAS与MCS的β系数为-2.38(95%CI -2.91至-1.86),BASFI与MCS的β系数为-1.10(95%CI -1.36至-0.84)。
- 自回归多变量模型中,ASDAS与ASQoL的β系数为1.18(95%CI 1.02至1.36),BASFI与ASQoL的β系数为1.08(95%CI 0.99至1.17)。
- BASFI对HRQoL的影响大于ASDAS。
- 中介分析显示ASDAS对HRQoL的效应大部分(约75%)由BASFI介导,但直接效应(约25%)也存在。
关键数值与推荐
- 自回归模型中ASDAS与PCS的β系数为-2.93(95%CI -3.28至-2.58),BASFI与PCS的β系数为-2.13(95%CI -2.31至-1.96)。
- 自回归模型中ASDAS与MCS的β系数为-2.38(95%CI -2.91至-1.86),BASFI与MCS的β系数为-1.10(95%CI -1.36至-0.84)。
- 自回归模型中ASDAS与ASQoL的β系数为1.18(95%CI 1.02至1.36),BASFI与ASQoL的β系数为1.08(95%CI 0.99至1.17)。
- 中介分析显示ASDAS对HRQoL的效应约75%由BASFI介导,直接效应约25%。
临床怎么用
- 在axSpA中,以低疾病活动度为目标对优化HRQoL至关重要。
- 疾病活动度对HRQoL的影响主要经功能损害介导,也存在直接效应。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aims to study the framework describing the longitudinal association between disease activity and function (independent variables) and health-related quality of life (HRQoL, outcome) in axial spondyloarthritis (axSpA). METHODS: Patients with AxSpA (symptoms <3 years) from the Devenir des Spondylarthropathies Indifferénciées Récentes cohort were followed up for 10 years. The association of disease activity (ASDAS) and function (BASFI) with HRQoL (physical component summary [PCS] and mental component summary [MCS] of 36-item short-form health survey, ankylosing spondylitis quality of life [ASQoL]) was assessed. Multivariable generalised estimating equations models were built with PCS, MCS, or ASQoL as outcomes (higher PCS/MCS = better HRQoL, higher ASQoL = worse), and ASDAS and BASFI as main predictors. Standard and autoregressive (i.e., corrected for prior HRQoL) models were used. The impact of ASDAS vs BASFI on HRQoL was compared through standardised coefficients. Mediation analysis assessed whether the effect of ASDAS on HRQoL was mediated by BASFI. Confounders/effect modifiers (eg, contextual factors) were considered in all models. RESULTS: A total of 663 patients with axSpA (46% males, mean age 33.5 [8.6] years) were included. In standard and autoregressive multivariable models, significant associations for ASDAS and BASFI with HRQoL were found (beta coefficient [95% CI] for autoregressive models: PCS -2.93 [-3.28, -2.58]; -2.13 [-2.31, -1.96]), MCS (-2.38 [-2.91, -1.86]; -1.10 [-1.36, -0.84]), ASQoL (1.18 [1.02, 1.36]; 1.08 [0.99, 1.17]). A larger influence of BASFI, compared to ASDAS, on HRQoL was noted. Mediation analysis showed the ASDAS effect on HRQoL was mostly (∼75%) mediated by BASFI, but a direct effect (∼25%) also existed. CONCLUSIONS: A validated longitudinal framework has been established for interpreting HRQoL: even correcting for contextual factors, disease activity consistently impacts HRQoL-primarily through functional impairment, but also directly. While HRQoL is an overarching outcome in axSpA, targeting low disease activity is crucial to optimise HRQoL.
引用
- Ortolan A, van der Heijde D, Gossec L, et al. Final validation of the hierarchical framework for outcomes in axial spondyloarthritis: longitudinal determinants of health-related quality of life. Ann Rheum Dis. 2025. PMID: 41238490. doi:10.1016/j.ard.2025.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。